Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung
Status:
Completed
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
Two-Year Disease Free Survival Rate of Stage IB~IIIA adenocarcinoma after Adjuvant
Chemotherapy with Pemetrexed and Cisplatin will be assessed. A total of 106 patients will be
recruited for 12 months, and followed for two years, thus the duration of study will be 36
months.
Phase:
Phase 2
Details
Lead Sponsor:
Chonnam National University Hospital
Collaborators:
Chungnam National University Hospital Korea University Guro Hospital Kosin University Gospel Hospital Kyungpook National University Kyungpook National University Hospital Pusan National University Hospital Severance Hospital